The visit formed part of the Annual Performance Review Meeting of the "THALIA 2021-2027" Cohesion Policy Programme and the European Commission's on-site visits to projects co-funded under the European Union's Cohesion Policy in Cyprus. 

During the visit, the representatives were introduced to Medicover Genetics' growth journey, its scientific and innovation activities, as well as its research project, co-funded by the EU under the RESTART Research and Innovation Programmes of the Research and Innovation Foundation (RIF), which form part of the Cohesion Policy Programme “THALIA 2021–2027“and its strategic contribution to strengthening Cyprus' position in the life sciences sector. Through presentations and discussions with the company's leadership and scientific teams, participants explored the role of European and national funding programmes in accelerating research and innovation, translating scientific knowledge into internationally recognised reproductive genetics and oncology solutions, and creating wider socioeconomic value through improved access to advanced diagnostics, highly skilled employment, and the development of a knowledge-based economy. 

Public investment achieves its greatest value when it extends beyond supporting research and delivers lasting scientific, societal, and economic impact. Its purpose not only funds innovation, but maximises the return on investment by translating research excellence into solutions that improve lives, strengthen healthcare systems, and reinforce Europe's competitiveness. 

Through sustained investment from European, national, and private funding programmes, Medicover Genetics has transformed innovation developed in Cyprus into internationally recognised reproductive genetics and oncology solutions that expand access to highly specialised diagnostics across Europe. By enabling earlier access to important health information, more personalised care, and improved patient outcomes, the company contributes to more equitable healthcare while advancing a knowledge-based economy built on scientific excellence, high-value employment, technological innovation, and international collaboration. This demonstrates how strategic investment in research can generate sustainable socioeconomic value that extends well beyond national borders, benefiting patients, healthcare systems, and society across Europe. 

Speaking during the visit, Dr Marios Ioannides, Managing Director of Medicover Genetics Cyprus said: 

"Medicover Genetics Cyprus demonstrates how scientific innovation developed in Cyprus can achieve global impact. The support provided through European, national, and private funding has enabled us to transform research excellence into internationally recognised diagnostic solutions that improve patient care, support highly skilled employment, and strengthen Cyprus' position as a regional centre for life sciences innovation. We remain committed to investing in research, advancing cutting-edge genomic technologies, and delivering lasting value for patients, healthcare systems, and society." 

The visit reaffirmed the importance of close collaboration between the public and private sectors in accelerating innovation, strengthening regional competitiveness, and supporting sustainable economic growth through investments in research, technology, and scientific excellence. 

For media enquiries, please contact: 

Mrs Pepa Tanousis, Marketing and Communications Director, Medicover Genetics, Cyprus 
communications.genetics@medicover.com 
+357 22 266 888  

About Medicover Genetics 

Medicover Genetics is a leading innovator in genetic diagnostics, laboratory enablement, and clinical testing, with over 25 years of experience supporting healthcare systems worldwide. The company offers a comprehensive portfolio of genetic testing services and clinical counselling, supported by certified diagnostic products and platforms. 

At the core of its offering is the proprietary Technology Transfer Platform—an end-to-end genomics solution that enables partner laboratories worldwide to perform high-precision genetic tests in-house. 

Medicover Genetics’ CE-marked, IVDR-certified portfolio, developed through decades of clinical and medical expertise, includes VERACITY™, a non-invasive prenatal test (NIPT), and TarCET™, a suite of clinical assays addressing hereditary cancers, cardiovascular and metabolic disorders, infertility, neonatal conditions, and other critical health areas. 

Driven by continuous research and development, Medicover Genetics is actively expanding into advanced areas such as liquid biopsy for therapy selection and minimal residual disease (MRD) testing. Its laboratories are CAP and ISO 15189 accredited, ISO 9001, and ISO 13485 certified, and comply with GMP and GCP, ensuring the highest quality standards. 

Medicover Genetics operates as a global organisation, working closely with laboratories and clinicians to deliver scalable, high-impact genetic solutions that support personalized medicine and enable informed clinical decision-making. www.medicover-genetics.com 

Medicover Genetics is part of Medicover, a leading international healthcare and diagnostic services company founded in 1995 and listed on Nasdaq Stockholm. www.medicover.com